Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay Mehta

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
BMJ Leader|September 28, 2022
Setting up an emergency medical task force to manage the demands of COVID-19: experiences of a London teaching hospitalPramit Khetrapal, Sophie Skarbek, Louis Tapper, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 30, 2017
High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti-Tumor Necrosis Factor TherapyNirit Mor-Vaknin, Miguel Rivas, Maureen Legendre, et al.
Medical Sciences (Basel, Switzerland)|November 25, 2024
Survival Outcomes of U.S. Patients with CMML: A Two-Decade Analysis from the SEER DatabaseAyrton Bangolo, Behzad Amoozgar, Abhishek Thapa, et al.
Frontiers in Oncology|October 31, 2022
The immune landscape of undifferentiated pleomorphic sarcomaRossana Lazcano, Carmelia M Barreto, Ruth Salazar, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 19, 2018
Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of TherapyClaas H Hinze, Dirk Foell, Anne L Johnson, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 1, 2018
Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis With Clinically Inactive DiseaseDaniel J Lovell, Anne L Johnson, Bin Huang, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
BMJ Leader|September 28, 2022
Setting up an emergency medical task force to manage the demands of COVID-19: experiences of a London teaching hospitalPramit Khetrapal, Sophie Skarbek, Louis Tapper, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 30, 2017
High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti-Tumor Necrosis Factor TherapyNirit Mor-Vaknin, Miguel Rivas, Maureen Legendre, et al.
Medical Sciences (Basel, Switzerland)|November 25, 2024
Survival Outcomes of U.S. Patients with CMML: A Two-Decade Analysis from the SEER DatabaseAyrton Bangolo, Behzad Amoozgar, Abhishek Thapa, et al.
Frontiers in Oncology|October 31, 2022
The immune landscape of undifferentiated pleomorphic sarcomaRossana Lazcano, Carmelia M Barreto, Ruth Salazar, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 19, 2018
Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of TherapyClaas H Hinze, Dirk Foell, Anne L Johnson, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 1, 2018
Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis With Clinically Inactive DiseaseDaniel J Lovell, Anne L Johnson, Bin Huang, et al.
Pageof 7